Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Covalent protein drugs developed via proximity-enabled reactive therapeutics (PERX)

A protein and drug technology, applied in the field of covalent protein drugs developed through proximity-enabling response therapy, which can solve the problems of lack of covalent reactivity of natural amino acid residues, selective application of reactions, obstacles, etc.

Pending Publication Date: 2021-07-27
HANGZHOU BRANCH OF TECH INST OF PHYSICS & CHEM CHINESE ACAD OF SCI
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The challenges in developing covalent protein drugs are as follows: native proteins interact primarily through non-covalent interactions and lack covalent reactivity to native amino acid residues on the target
Additionally, the ubiquitous presence of amino acids in proteins, cells, and in vivo imposes a formidable barrier to achieving reaction selectivity against a target

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Covalent protein drugs developed via proximity-enabled reactive therapeutics (PERX)
  • Covalent protein drugs developed via proximity-enabled reactive therapeutics (PERX)
  • Covalent protein drugs developed via proximity-enabled reactive therapeutics (PERX)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Cloning of human PD-1 and PD-L1 extracellular IgV domains

[0109] Protein stability aided by replacement of human PD-1 (hPD-1) IgV domain encoding gene (residues 32-160, Cys93 with Ser (C93S) 28 ) into the pET-26b vector with a carboxy-terminal 6x histidine tag to generate plasmid pET-26b-PD1(WT) (SEQ ID NO: 15 and 22). Briefly, plasmid pUC57-Kan-hPD-1 IgV domain (32 -160, C93S) to amplify the DNA of the hPD-1 IgV domain (32-160, C93S), which was codon-optimized and synthesized by GENEWIZ (China, Suzhou). The PCR product was digested with NdeI-HF and XhoI-HF and ligated into the pre-cut pET-26b vector using T4 DNA ligase (NEB, catalog number M0202L).

[0110] PD-1 WT-F:GTTAGACTcatatgTGGAATCCGCCGACCTTTAGC (SEQ ID NO:1)

[0111] PD-1 WT-R: ACTGctcgagCGGACTAGGACTCGGATGTGCG (SEQ ID NO: 2)

[0112] To introduce a TAG codon at site D77 or A129, overlap PCR was performed using Q5 high-fidelity DNA polymerase and using plasmid pET-26b-PD1(WT) as a template using the follow...

Embodiment 2

[0130] Expression and purification of human PD-1 IgV domain and PD-L1 IgV domain

[0131] Plasmids pET-26b-PD1(WT), pET-26b-PD-L1(WT) and pET-26b-PD-L1(H69A) were individually transformed into E. coli BL21(DE3) electrocompetent cells. Plasmid pET-26b-PD-1(Q75TAG), pET-26b-PD-1(D77TAG) or pET-26b-PD-1(A129TAG) each with plasmid pEvol-FSYRS 29 Co-transformation into Escherichia coli BL21 (DE3) electrocompetent cells.

[0132] For the expression of PD-1(WT), PD-L1(WT) and PD-L1(H69A), the transformed bacteria were cultured at 37°C in 2xYT medium containing 50 μg / mL kanamycin, and when OD 600 Induction with 1 mM IPTG when reaching 0.8. For FSY incorporation into proteins, the transformed bacteria were cultured at 37°C in 2xYT medium containing 50 μg / mL kanamycin and 34 μg / mL chloramphenicol, and when OD 600 At 0.8 it was induced with 1 mM IPTG, 0.2% arabinose and 1 mM FSY.

[0133]After induction of expression for 12 hours, bacteria were harvested by centrifugation at 7000 rpm...

Embodiment 3

[0140] Cross-linking of PD-1(FSY) and PD-L1

[0141] 3.1 In vitro cross-linking of PD-1(FSY) and PD-L1

[0142] Purified and refolded PD-1(WT), PD-1(Q75FSY), PD-1(D77FSY) or PD-1(A129FSY) and PD-L1(WT) or PD-L1(H69A) at a ratio of 1:1 The molar ratios were incubated in PBS buffer at 37 °C for 6 h. The amount of PD-L1 was 4 μg. After incubation, 5x reducing loading buffer (CWBio, cat# CW0027) was added to the incubation and heated at 100°C for 10 min. These samples were then separated by 15% SDS-PAGE gels followed by Coomassie blue staining. Then use a primary antibody specific for the His6x tag (mAb anti-6xHis tag, Abcam, Cat. No. 18184, 1:1000 dilution) and a secondary antibody goat pAb anti-mouse IgG (Abcam, Cat. No. 97023, 1:5000 dilution) Perform western blotting. Protein bands were visualized by chemiluminescence (Bio-rad, catalog #1705062).

[0143] 3.2 Mass spectrometry analysis

[0144] PD-1(FSY) and PD-1(FSY) / PD-L1 cross-linked protein samples were digested wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided a proximity-enabled reactive therapeutics (PERx) approach to generate covalent protein drugs. A latent bioreactive amino acid FSY was incorporated into human programmed cell death protein 1 (PD-1), which selectively reacted with a proximal histidine of human PD-L1 upon binding, enabling irreversible binding of PD-1 with PD-L1 in vitro, on cancer cells, and in tumor in mice. When administrated in humanized mouse models, the covalent PD-1 (FSY) exhibited robust antitumor effect over wildtype PD-1, achieving therapeutic efficacy equivalent to the FDA approved therapeutic monoclonal antibody atezolizumab. The PERx approach should provide a general method for converting interacting proteins into covalent protein drugs for high therapeutic efficacy.

Description

[0001] sequence listing [0002] This application is filed together with a Sequence Listing in electronic form. The entire content of the Sequence Listing is incorporated herein by reference. technical field [0003] The present application relates generally to methods of proximity-enabled response therapy for the generation of covalent protein drugs, and muteins comprising a potentially bioreactive unnatural amino acid (Uaa) that can be used to pass the proximity-enabled response therapy ( Proximity-enabled reactive therapeutics) developed covalent protein drugs. More specifically, the present application relates to a mutated PD-1 comprising o-fluorosulfate-L-tyrosine (fluorosulfate-L-tyrosine, FSY), its preparation method, and the application of the mutated PD-1. Background technique [0004] Small molecule drugs that covalently bind their targets have reemerged in recent years with great success, although historically shunned by pharmaceutical researchers and industry ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/197C07K1/113C07C381/02A61K31/198A61P35/00
CPCC07K1/113A61P35/00
Inventor 王谦
Owner HANGZHOU BRANCH OF TECH INST OF PHYSICS & CHEM CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com